

June 04, 2026

To,
The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code - 500672

Sub.: Intimation of Recommendations by the Committee of Independent Directors ("IDC") pursuant to Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and takeovers) Regulations, 2011 ("SEBI SAST Regulations").

Dear Sir/ Madam,

Pursuant to Regulation 26(7) of the SEBI SAST Regulations, we hereby inform that a meeting of the Committee of Independent Directors ("IDC") of Novartis India Limited ("The Company/ Target Company") formed under Regulation 26(6) of the SEBI SAST Regulations was held on Thursday, June 04, 2026 at 04:30 p.m. (IST), on the open offer by WaveRise Investments Limited ("Acquirer 1"), ChrysCapital Fund X, the first scheme of ChrysCapital Trust I, a category II alternative investment fund registered with SEBI ("Acquirer 2") and Two Infinity Partners ("Acquirer 3") (Acquirer 1, Acquirer 2 and Acquirer 3, collectively referred to as the ("Acquirers"), along with ChrysCapital X, LLC ("PAC 1") and OceanEdge Investments Limited ("PAC 2") (PAC 1 and PAC 2, collectively referred to as the "PACs"), to the public shareholders of the Company for acquiring up to 64,19,608 (Sixty Four Lakh Nineteen Thousand Six Hundred and Eight) fully paid-up equity shares having a face value of INR 5 (Indian Rupees Five) each ("Equity Shares") of the Target Company, representing 26% (Twenty Six percent) of the total voting Share Capital at an offer price of INR 860.64 (Indian Rupees Eight Hundred Sixty and Sixty Four Paise) per equity share.

The IDC provided their reasoned recommendations in connection with the Open Offer made under the SEBI SAST Regulations after review of the Detailed Public Statement, the Letter of Offer and the Valuation Report.

A copy of the said reasoned recommendations of the IDC is enclosed herewith for your information and records.

Thanking You.
Yours sincerely,

For Novartis India Limited

CHANDNI
BHUPENDRA
MARU

Digitally signed by
CHANDNI BHUPENDRA
MARU
Date: 2026.06.04 22:59:01
+05'30'

Chandni Maru
Company Secretary and Compliance Officer
A60291

Encl.: as above

Recommendations of the Committee of Independent Directors (“IDC”) of Novartis India Limited (“Target Company”) on the Open Offer for acquisition of up to 64,19,608 (Sixty Four Lakh Nineteen Thousand Six Hundred and Eight) fully paid-up equity shares having a face value of INR 5 (Indian Rupees Five) each (“Equity Shares”) of the Target Company, representing 26% (Twenty Six per cent.) of the Voting Share Capital, from the Public Shareholders of the Target Company, by WaveRise Investments Limited (“Acquirer 1”), ChrysCapital Fund X, the first scheme of ChrysCapital Trust I, a category II alternative investment fund registered with SEBI (“Acquirer 2”) and Two Infinity Partners (“Acquirer 3”) (Acquirer 1, Acquirer 2 and Acquirer 3, collectively referred to as the (“Acquirers”), along with ChrysCapital X, LLC (“PAC 1”) and OceanEdge Investments Limited (“PAC 2”) (PAC 1 and PAC 2, collectively referred to as the “PACs”), in their capacity as persons acting in concert with the Acquirers for the purposes of the Open Offer, pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (“SEBI (SAST) Regulations”) (the “Offer” / “Open Offer”).

Sr. No.	Particulars	Details
1	Date	Thursday, June 04, 2026
2	Name of the Target Company	Novartis India Limited
3	Details of the Offer pertaining to Target Company	The Open Offer has been made by WaveRise Investments Limited, ChrysCapital Fund X, the first scheme of ChrysCapital Trust I and Two Infinity Partners, (“Acquirers”) along with ChrysCapital X, LLC and OceanEdge Investments Limited, being persons acting in concert (“PACs”) along with the Acquirers, for acquisition of up to 64,19,608 fully paid-up equity shares having a face value of INR 5 each, representing 26% of the total voting share capital of the Target Company, at an offer price of INR 860.64 (Indian Rupees Eight Hundred Sixty and Sixty Four Paise) per equity share, pursuant to Regulations 3(1) and 4 of the SEBI (SAST) Regulations (“Offer Price”). The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers (“Public Announcement”) pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company (“Share Purchase Agreement”). The detailed public statement published on February 26, 2026, the draft letter of offer filed with



		SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the manager to the Open Offer on behalf of the Acquirers and the PACs.
4	Name(s) of the acquirer and PAC with the acquirer	Acquirers: WaveRise Investments Limited, ChrysCapital Fund X, the first scheme of ChrysCapital Trust I and, Two Infinity Partners. PACs: ChrysCapital X, LLC and OceanEdge Investments Limited.
5	Name of the Manager to the offer	Axis Capital Limited Axis House, 1st Floor, Pandurang Budhkar Marg, Worli, Mumbai - 400 025, Maharashtra, India Tel: +91 22 4325 2183 Fax: +91 22 4325 3000 E-mail: novartis.openoffer@axiscap.in Contact Person: Pratik Pednekar SEBI Registration No.: INM000012029
6	Members of the Committee of Independent Directors	Mr. Sanker Parameswaran – Chairperson and Member of the IDC Ms. Gira Jagdeesh Sardesai – Member Ms. Gowree Gokhale – Member
7	IDC Member's relationship with the TC (Director, Equity shares owned, any other contract / relationship), if any	The members of the IDC are Independent Directors on the Board of the Target Company. Save and except for their directorships, none of the members of the IDC have any relationship or contract with the Target Company, and none of them hold any equity shares or other securities of the Target Company.
8	Trading in the Equity shares/other securities of the TC by IDC Members	None of the members of the IDC have traded in any equity shares or other securities of the Target Company during the 12 months period preceding the date of the Public Announcement and during the period from the date of the Public Announcement till the date of this recommendation.
9	IDC Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any	None of the members of the IDC are Directors on the Board/s of the Acquirers or PACs, hold any equity shares or other securities of the Acquirers or PACs, or have any contracts or relationship with them.



10	Trading in the Equity shares/other securities of the acquirer by IDC Members	None of the members of the IDC have traded in any equity shares or other securities of the Acquirers or PACs during the 12 months period preceding the date of the Public Announcement and during the period from the date of the Public Announcement till the date of this recommendation.
11	Recommendation on the Open Offer, as to whether the offer is fair and reasonable	Based on the documents and materials placed before IDC as below: - - the Public Announcement by Acquirers dated February 19, 2026, - the Detailed Public Statement by Acquirers dated February 26, 2026, - the Letter of Offer dated June 01, 2026, issued by the Acquirers in which Offer price of INR 860.64 (Indian Rupees Eight Hundred Sixty and Sixty Four Paise) per share is mentioned, - valuation report from A R C H and Associates, Chartered Accountants dated June 01, 2026 appointed by Target Company (as attached). The IDC believes that the Offer Price is in accordance with the applicable provisions of the SEBI (SAST) Regulations and appears to be fair and reasonable from the perspective of the regulatory pricing framework applicable to the Open Offer.
12	Summary of reasons for recommendation	The IDC noted that the Open Offer has been triggered pursuant to the proposed acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company from Novartis AG and the consequent acquisition of control over the Target Company. In arriving at its recommendation, the IDC reviewed and considered the below mentioned documents along with the pricing framework prescribed under Regulation 8 of the SEBI (SAST) Regulations, 2011. - the Public Announcement by Acquirers dated February 19, 2026, - the Detailed Public Statement by Acquirers dated February 26, 2026 - the Letter of Offer dated June 01, 2026, issued by the Acquirers in which Offer price of INR



		860.64 (Indian Rupees Eight Hundred Sixty and Sixty Four Paise) per share is mentioned. • valuation report from A R C H and Associates, Chartered Accountants dated June 01, 2026 appointed by Target Company (as attached) The IDC further noted that the equity shares of the Target Company are frequently traded and that the offer price has been determined in accordance with the applicable provisions of the SEBI (SAST) Regulations. Based on the above and having regard to the information available to it, the IDC is of the view that the offer price is in accordance with the applicable provisions of the SEBI (SAST) Regulations and is fair and reasonable from the perspective of the regulatory pricing framework applicable to the Open Offer. Accordingly, the IDC recommends the Open Offer to the public shareholders of the Target Company for their consideration. Public shareholders are advised to independently evaluate the Open Offer, taking into account their individual circumstances, investment objectives, risk factors described in the Letter of Offer and other relevant considerations before taking a decision with respect to tendering their equity shares in the Open Offer. The IDC would like to draw attention that the closing market price of equity shares on June 04, 2026 was INR 1351.20 (Indian Rupees One Thousand Three Hundred Fifty-One and Twenty Paise) (as per the BSE) per equity share, which is higher than the Offer Price. This statement of recommendation will also be available on the website of the Target Company.
13	Details of Independent Advisors, if any	The Valuation Report issued by A R C H and Associates, Chartered Accountants confirming that the Offer Price is in accordance with Regulation 8(2) of the SEBI (SAST) Regulations. A R C H AND ASSOCIATES, Chartered Accountants Firm Registration No. 152180W



		1804, Anmol Pride, Opp. Patel Petrol Pump, S.V. Road, Goregaon (West), Mumbai – 400 104.
14	Any other matter(s) to be highlighted	The IDC has no other matters to highlight other than the following: The IDC would like to draw attention that the closing market price of equity shares on June 04, 2026 was INR 1351.20 (Indian Rupees One Thousand Three Hundred Fifty-One and Twenty Paise) (as per the BSE) per equity share, which is higher than the Offer Price.
15	Disclosure of Voting Pattern	The recommendation was unanimously approved by all the members of the IDC present at the meeting held on June 04, 2026.
16	Responsibility Statement	To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations.

For and on behalf of the Committee of Independent Directors of Novartis India Limited



Sanker Parameswaran
Chairperson – Committee of Independent Directors.



Date: June 04, 2026,
Place: Mumbai

Enclosure: - as above

A R C H AND ASSOCIATES

Chartered Accountants

1st June 2026

To,

Novartis India Limited

Inspire BKC, 7th Floor,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Sub: Computation of minimum price of equity shares of Novartis India Limited for the open offer in accordance with the provisions of Regulation 8(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

We refer to our engagement letter dated 16th March 2026, whereby A R C H AND ASSOCIATES, Chartered Accountants (hereinafter referred to as "the Valuer" or "We") have been appointed by Novartis India Limited [CIN:L24200MH1947PLC006104] (hereinafter referred to as "Novartis" or "the Company") to compute minimum price of the equity shares of the Company for the open offer in accordance with the provisions of Regulation 8(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

In the following paragraphs, we have summarized our understanding of the key facts, key information relied upon, our approach and exclusions to the scope of work.

The report is structured as under:

1. Purpose of Report
2. Background
3. Sources of Information
4. Our Approach
5. Recommendation
6. Exclusions and Disclaimers

We hereby state that we have carried out the exercise in our capacity as an independent valuer. We further state that we are not related to the Company or its promoters or its directors or their relatives. As on the date of this report, we have no interest or conflict of interest with respect to the report under consideration.

Page 1 of 8

Cell No: +91 99870 65322
+91 90043 57775
e-mail: rahul@arch-associates.com
harsh@arch-associates.com



1804, Anmol Pride,
Opp. Patel Petrol Pump,
S.V. Road, Goregaon (West),
Mumbai – 400 104

1. PURPOSE OF REPORT

- 1.1. We understand that the management of the Company is desirous of determining minimum price of equity shares of the Company as per Regulation 8(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The present exercise is undertaken for consideration of the Committee of the Independent Directors for their assessment of the fair value of the equity shares offered by the Acquirer in relation to the open offer of the shares of the Company. The public announcement for the aforesaid open offer was made on 19th February 2026.
- 1.2. In this regard, A R C H AND ASSOCIATES, Chartered Accountants have been appointed to compute the minimum price of equity shares under Regulation 8(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and issue a report for the minimum price under the aforesaid SEBI Regulations.

2. BACKGROUND

2.1. NOVARTIS INDIA LIMITED ("NOVARTIS")

- 2.1.1. Novartis was incorporated on 13th December 1947 under the provisions of the erstwhile Companies Act, 1913. The registered office of the Company is currently situated at Inspire BKC, 7th Floor Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.
- 2.1.2. The equity shareholding pattern of the Company as on 31st December 2025 is as under:

Sr. No.	Category of the Shareholder	No. of shares held	Shareholding (%)
1	Promoter & Promoter Group	1,74,50,680	70.68%
2	Public	72,40,117	29.32%
	Total	2,46,90,797	100.00%

Source: <https://www.bseindia.com>

The management has informed that there is no change in the number of shares as on 19th February 2026.

- 2.1.3. The Company is engaged in the business of manufacturing of medicine and other pharmaceuticals.

3. SOURCES OF INFORMATION

- 3.1. For the purpose of this exercise, we have relied upon the following sources of information:

- (a) Audited financial statements of the Company for the year ended 31st March 2025, as available in the public domain;
- (b) Market price and volume information of the Company as available on BSE;
- (c) Latest shareholding pattern of the Company based on information, as available in the public domain;
- (d) Other relevant details of the Company such as its history, past and present activities, future plans and prospects, and other relevant information; and
- (e) Such other information and explanations as required and which have been provided by the management of the Company.

Besides the above information and documents, there may be other information provided by the Company which may not have been perused by us in any detail, if not considered relevant for the defined scope. The Company has been provided with the opportunity to review the draft report as part of our standard practice to make sure that factual inaccuracy & omissions are avoided in the final report.

4. OUR APPROACH

- 4.1. For the purpose of determining minimum price of equity shares of the Company as per Regulation 8(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 the offer price shall be the highest of:
- (a) the highest negotiated price per share of the target company for any acquisition under the agreement attracting the obligation to make a public announcement of an open offer;
 - (b) the volume-weighted average price paid or payable for acquisitions, whether by the acquirer or by any person acting in concert with him, during the fifty-two weeks immediately preceding the date of the public announcement;
 - (c) the highest price paid or payable for any acquisition, whether by the acquirer or by any person acting in concert with him, during the twenty-six weeks immediately preceding the date of the public announcement;
 - (d) the volume-weighted average market price of such shares for a period of sixty trading days immediately preceding the date of the public announcement as traded on the stock exchange where the maximum volume of trading in the shares of the target company are recorded during such period, provided such shares are frequently traded;
 - (e) where the shares are not frequently traded, the price determined by independent registered valuer taking into account valuation parameters

including, book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies; or
(f) the per share value computed under sub-regulation (5), if applicable i.e. for indirect acquisition of shares.

- 4.2. The management has informed that the acquisition is a direct acquisition of shares of the Company and therefore, the Regulation for indirect acquisition of shares [Regulation 8(2)(f)], shall not apply.
- 4.3. As per the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, "frequently traded shares" means shares of a target company, in which the traded turnover on any stock exchange during the twelve calendar months preceding the calendar month in which the public announcement [is required to be made under these regulations], is at least ten per cent of the total number of shares of such class of the target company.
- 4.4. The total number of shares traded during the 12 calendar months preceding the calendar month in which public announcement is made is 24,94,106 and the percentage of shares traded as a percent of the total number of shares is 10.10%, computed as under:

Particulars	Number of shares
Total number of shares (as per shareholding pattern as on 31 December 2025) *	2,46,90,797
Total number of shares traded during the 12 calendar months preceding the calendar month in which public announcement is made (1 February 2025 to 31 January 2026)	24,94,106
Shares Traded / Total Number of Shares	10.10%

Accordingly, the Regulation for not frequently traded shares [Regulation 8(2)(e)] shall not apply.

5. RECOMMENDATION

- 5.1. In light of the above and on consideration of all the relevant factors and circumstances as discussed and outlined herein in this report (including exclusions and disclaimers, provided below), the minimum price of equity shares as per Regulation 8(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, shall be higher of the following:

<<This space has been intentionally left blank>>



Sr. no.	Particulars	Price (INR)	Reference
a)	the highest negotiated price per share of the target company for any acquisition under the agreement attracting the obligation to make a public announcement of an open offer	860.64	The management has informed that the highest negotiated price as per the Share Purchase Agreement is INR 860.64
b)	the volume-weighted average price paid or payable for acquisitions, whether by the acquirer or by any person acting in concert with him, during the fifty-two weeks immediately preceding the date of the public announcement	Not Applicable	The management has informed that the acquirer or PAC are the first time investors in the Company and have never held the shares of the Company earlier
c)	the highest price paid or payable for any acquisition, whether by the acquirer or by any person acting in concert with him, during the twenty-six weeks immediately preceding the date of the public announcement	Not Applicable	The management has informed that the acquirer or PAC are the first time investors in the Company and have never held the shares of the Company earlier
d)	the volume-weighted average market price of such shares for a period of sixty trading days immediately preceding the date of the public announcement as traded on the stock exchange where the maximum volume of trading in the shares of the target company are recorded during such period, provided such shares are frequently traded	803.57	Refer detailed computation - Annexure A
e)	where the shares are not frequently traded, the price determined by an independent registered valuer taking into account valuation parameters including, book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies	Not Applicable	The shares of the Company are frequently traded as per the definition provided under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
f)	the per share value computed under sub-regulation (5), if applicable.	Not Applicable	As informed by the management, this is a direct acquisition of shares

Accordingly, the minimum price of equity shares in terms of Regulation 8(2) of SEBI (Substantial Acquisition of Shares and Takeovers), 2011 shall be INR 860.64/- per equity share.

6. EXCLUSIONS AND DISCLAIMERS

- 6.1. The report is subject to the exclusions and disclaimers detailed hereinafter. As such, the report is to be read in totality, and not in parts, in conjunction with the relevant documents referred to herein.
- 6.2. No investigation of the Company's claim to title of assets has been made for the purpose of this report and their claim to such rights has been assumed to be valid. Therefore, no responsibility is assumed for matters of legal nature.
- 6.3. The recommendation under this report involves consideration of various factors based on prevailing stock market, financial, economic and other conditions including those impacted by prevailing market trends in general and industry trends in particular.
- 6.4. The work does not constitute certification of the financial statements including the working results of the Company referred to in this report. Accordingly, we are unable to and do not express an opinion on the fairness or accuracy of any financial information referred to in this report. The results are specific to the purpose of this report and the announce date for open offer mentioned in the report is as per agreed terms of the engagement. It may not be valid or used for

AP

any other purpose or as at any other date. Also, it may not be valid if done on behalf of any other entity.

- 6.5. This report does not look into the business / commercial reasons behind the transaction or address any potential synergies to the Company, or any other parties connected thereto.
- 6.6. In the course of the exercise, we were provided with both written and verbal information. We have evaluated the information provided to us by the management of the Company through broad inquiry, analysis and review. We assume no responsibility for any errors in the above information furnished by the management of the Company and consequential impact on the present exercise. We do not express any opinion or offer any assurance regarding accuracy or completeness of any information made available to us.
- 6.7. The report is not, nor should it be construed as opining or certifying any compliance with the provisions of any law, whether in India or any other country including companies, taxation and capital market related laws or as regards any legal implications or issues arising from any transaction to be contemplated based on this report.
- 6.8. Any person/party intending to provide finance/invest in the shares/securities/instruments/assets/businesses of the Company, shall do so, after seeking their own professional advice and after carrying out their own due diligence procedures to ensure that they are making an informed decision. It is to be noted that any reproduction, copying or otherwise quoting of this report or any part thereof, can be done only after obtaining prior permission in writing.
- 6.9. This report is prepared solely for the purpose of assisting the Company, under consideration, in recommending the minimum price as per Regulation 8(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for internal management purposes only. Further, the fees for this engagement is not contingent upon the results arrived under this exercise.
- 6.10. A R C H AND ASSOCIATES, nor its partners or employees or agents or any of them, makes any representation or warranty, express or implied, as to the accuracy, reasonableness or completeness of the information, based on which the report is issued. All such parties expressly disclaim any and all liability for, or based on or relating to any such information contained in the report. We are not liable to any third party in relation to issue of this report. In no event, we shall be liable for any loss, damage, cost or expense arising in any way from any acts carried out by the Company or any person connected thereto.



A R C H AND ASSOCIATES
Chartered Accountants

If you require any clarifications on the above, we would be happy to clarify the same.
We are thankful to your team for kind co-operation and support during this assignment.

Thanking You,

For **A R C H AND ASSOCIATES**

Chartered Accountants

Firm Registration No. 152180W

Harsh C Digitally signed by
Harsh C Ruparelia
Ruparelia Date: 2026.06.01
12:29:31 +05'30'

CA Harsh Ruparelia

Partner

Membership No. 160171

Date: 1st June 2026

Place: Mumbai

UDIN: 26160171CADUFT7417



Annexure – A

Computation of the volume-weighted average market price for a period of sixty trading days immediately preceding the date of the public announcement as on 19th February 2026 [Regulation 8(2)(d)]

Date	Volume	Turnover	Date	Volume	Turnover
18-Feb-26	18,160	1,53,38,019	06-Jan-26	17,055	1,36,34,293
17-Feb-26	5,698	47,21,700	05-Jan-26	7,633	59,92,106
16-Feb-26	1,47,863	12,26,16,280	02-Jan-26	11,047	86,09,226
13-Feb-26	12,198	97,57,833	01-Jan-26	5,823	45,27,872
12-Feb-26	5,778	47,84,554	31-Dec-25	3,815	29,76,570
11-Feb-26	5,281	43,87,093	30-Dec-25	5,372	41,94,934
10-Feb-26	5,766	48,41,788	29-Dec-25	4,262	33,20,888
09-Feb-26	9,184	76,56,826	26-Dec-25	6,188	48,62,275
06-Feb-26	6,354	52,37,508	24-Dec-25	4,399	34,61,351
05-Feb-26	5,130	42,10,919	23-Dec-25	3,791	29,76,644
04-Feb-26	34,985	2,86,99,209	22-Dec-25	11,866	92,92,794
03-Feb-26	4,791	37,08,795	19-Dec-25	5,492	43,15,775
02-Feb-26	3,546	27,05,943	18-Dec-25	5,733	44,94,784
01-Feb-26	8,155	62,71,411	17-Dec-25	2,438	18,95,099
30-Jan-26	11,644	88,59,806	16-Dec-25	17,859	1,38,71,605
29-Jan-26	15,974	1,22,66,529	15-Dec-25	11,366	90,59,849
28-Jan-26	45,187	3,63,52,363	12-Dec-25	30,142	2,41,86,521
27-Jan-26	6,859	54,21,731	11-Dec-25	15,557	1,24,51,692
23-Jan-26	5,446	43,11,933	10-Dec-25	9,847	77,70,128
22-Jan-26	5,448	42,22,193	09-Dec-25	5,167	41,02,418
21-Jan-26	18,046	1,37,73,838	08-Dec-25	4,962	39,07,189
20-Jan-26	3,735	29,26,065	05-Dec-25	12,015	94,64,298
19-Jan-26	4,079	32,53,770	04-Dec-25	1,00,611	8,02,33,591
16-Jan-26	3,644	29,02,916	03-Dec-25	3,088	25,05,119
14-Jan-26	3,674	28,94,905	02-Dec-25	3,046	24,68,365
13-Jan-26	3,886	30,38,609	01-Dec-25	2,701	21,88,416
12-Jan-26	6,340	50,13,290	28-Nov-25	5,343	43,27,356
09-Jan-26	7,504	60,05,408	27-Nov-25	3,457	28,07,528
08-Jan-26	6,062	48,52,681	26-Nov-25	6,021	49,00,237
07-Jan-26	8,849	70,84,941	25-Nov-25	7,263	59,06,327
Total Turnover					61,28,24,106
Total Volume					7,62,625
VOLUME WEIGHTED AVERAGE PRICE (In INR) - 60 TRADING DAYS					803.57

AR